Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174

The response to primary immunization in patients treated with Rituximab (RIT) is not clear. We studied the in vivo antibody response of chronic renal failure (CRF) patients to the neoantigen bacteriophage phiX174 given alone or after ablation with RIT. Eighteen CRF subjects received two immunization...

Full description

Saved in:
Bibliographic Details
Published in:American journal of transplantation 2005-01, Vol.5 (1), p.50-57
Main Authors: Bearden, Christopher M., Agarwal, Avinash, Book, Benita K., Vieira, Carlos A., Sidner, Richard A., Ochs, Hans D., Young, Marquerite, Pescovitz, Mark D.
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal, Murine-Derived
Antibodies, Viral - chemistry
Antibody Formation
Antineoplastic Agents - pharmacology
B lymphocytes
B-Lymphocytes - immunology
Bacteriophage phi X 174 - immunology
Body Weight
CD20
Female
Graft Survival
human
Humans
Immunization
Immunoglobulins - chemistry
Immunophenotyping
Kidney Failure, Chronic - drug therapy
Kidney Failure, Chronic - microbiology
Male
memory
Middle Aged
Rituximab
Time Factors
tolerance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The response to primary immunization in patients treated with Rituximab (RIT) is not clear. We studied the in vivo antibody response of chronic renal failure (CRF) patients to the neoantigen bacteriophage phiX174 given alone or after ablation with RIT. Eighteen CRF subjects received two immunizations with phiX174 separated by 6 weeks. Nine subjects received a single dose of RIT. The intensity and immunoglobulin isotype of the antibody response (Kv) were measured post‐infusion. In addition, three subjects previously immunized and treated with RIT underwent a third and fourth immunization with phiX174 and a tetanus control 2 years later. RIT significantly decreased peak Kv responses when compared to both historic non‐CRF controls and to CRF subjects. CRF itself decreased peak Kv responses compared to non‐CRF controls. Percent‐ratio of anti‐phage IgM to IgG was significantly decreased in RIT treated subjects. One of three subjects treated with RIT was found to have developed a partial B cell tolerance to phiX174 administration 2 years later. RIT decreases antibody production and isotype switching to neoantigens and might be useful to prevent antibody response to therapeutic drugs and to newly transplanted organs.
ISSN:1600-6135
1600-6143
DOI:10.1111/j.1600-6143.2003.00646.x